{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:50:41Z","timestamp":1794088241682,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41401-019-0280-2","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T07:04:05Z","timestamp":1565075045000},"page":"1503-1512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["TLR4 deficiency has a protective effect in the MPTP\/probenecid mouse model of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"40","author":[{"given":"Qian-hang","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-he","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"280_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.irn.2017.01.004","volume":"132","author":"R Erro","year":"2017","unstructured":"Erro R, Stamelou M. The motor syndrome of Parkinson\u2019s disease. Int Rev Neurobiol. 2017;132:25\u201332.","journal-title":"Int Rev Neurobiol"},{"key":"280_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fnagi.2018.00109","volume":"10","author":"XS Zeng","year":"2018","unstructured":"Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci. 2018;10:109.","journal-title":"Front Aging Neurosci"},{"key":"280_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3109\/00207454.2014.982795","volume":"125","author":"S Vivekanantham","year":"2015","unstructured":"Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R. Neuroinflammation in Parkinson\u2019s disease: role in neurodegeneration and tissue repair. Int J Neurosci. 2015;125:717\u201325.","journal-title":"Int J Neurosci"},{"key":"280_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/ajmg.b.30758","volume":"147b","author":"DM Kay","year":"2008","unstructured":"Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, et al. Genetic association between alpha-synuclein and idiopathic Parkinson\u2019s disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147b:1222\u201330.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"280_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00441-017-2775-9","volume":"373","author":"V Grozdanov","year":"2018","unstructured":"Grozdanov V, Danzer KM. Release and uptake of pathologic alpha-synuclein. Cell Tissue Res. 2018;373:175\u201382.","journal-title":"Cell Tissue Res"},{"key":"280_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F. Mechanisms of alpha-Synuclein induced synaptopathy in Parkinson\u2019s disease. Front Neurosci. 2018;12:80.","journal-title":"Front Neurosci"},{"key":"280_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12035-012-8267-8","volume":"47","author":"CM Lema Tome","year":"2013","unstructured":"Lema Tome CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. Inflammation and alpha-synuclein\u2019s prion-like behavior in Parkinson\u2019s disease-is there a link? Mol Neurobiol. 2013;47:561\u201374.","journal-title":"Mol Neurobiol"},{"issue":"Suppl 1","key":"280_CR8","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S1353-8020(11)70008-6","volume":"18","author":"D Beraud","year":"2012","unstructured":"Beraud D, Maguire-Zeiss KA. Misfolded alpha-synuclein and toll-like receptors: therapeutic targets for Parkinson\u2019s disease. Park Relat Disord. 2012;18(Suppl 1):S17\u201320.","journal-title":"Park Relat Disord"},{"key":"280_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/glia.1106","volume":"36","author":"F Aloisi","year":"2001","unstructured":"Aloisi F. Immune function of microglia. Glia. 2001;36:165\u201379.","journal-title":"Glia"},{"issue":"6","key":"280_CR10","doi-asserted-by":"publisher","first-page":"pyu103","DOI":"10.1093\/ijnp\/pyu103","volume":"18","author":"J. Drouin-Ouellet","year":"2014","unstructured":"Drouin-Ouellet J, St-Amour I, Saint-Pierre M, Lamontagne-Proulx J, Kriz J, Barker RA, et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson\u2019s disease. Int J Neuropsychopharmacol.\u00a02014;18: pii: pyu103. \nhttps:\/\/doi.org\/10.1093\/ijnp\/pyu103\n\n.","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"280_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep01393","volume":"3","author":"C Noelker","year":"2013","unstructured":"Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep. 2013;3:1393.","journal-title":"Sci Rep"},{"issue":"8","key":"280_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41401-018-0209-1","volume":"40","author":"Ying Chen","year":"2019","unstructured":"Chen Y, Zhang QS, Shao QH, Wang S, Yuan YH, Chen NH, et al. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. Acta Pharmacol Sin. 2019; 40: (in press).\u00a0\nhttps:\/\/doi.org\/10.1038\/s41401-018-0209-1\n\n. [Epub ahead of print]","journal-title":"Acta Pharmacologica Sinica"},{"key":"280_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1124\/jpet.117.244020","volume":"363","author":"QS Zhang","year":"2017","unstructured":"Zhang QS, Heng Y, Chen Y, Luo P, Wen L, Zhang Z, et al. A novel bibenzyl compound (20C) protects mice from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\/probenecid toxicity by regulating the alpha-synuclein-related inflammatory response. J Pharmacol Exp Ther. 2017;363:284\u201392.","journal-title":"J Pharmacol Exp Ther"},{"key":"280_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-7","volume":"5","author":"SS Shaftel","year":"2008","unstructured":"Shaftel SS, Griffin WS, O\u2019Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation. 2008;5:7.","journal-title":"J Neuroinflammation"},{"key":"280_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.intimp.2017.05.027","volume":"49","author":"QH Shao","year":"2017","unstructured":"Shao QH, Zhang XL, Yang PF, Yuan YH, Chen NH. Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome. Int Immunopharmacol. 2017;49:155\u201360.","journal-title":"Int Immunopharmacol"},{"key":"280_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1753425913484374","volume":"20","author":"G Sollberger","year":"2014","unstructured":"Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. Innate Immun. 2014;20:115\u201325.","journal-title":"Innate Immun"},{"key":"280_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/BJ20150617","volume":"471","author":"A Gustot","year":"2015","unstructured":"Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson\u2019s disease. Biochem J. 2015;471:323\u201333.","journal-title":"Biochem J"},{"key":"280_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12640-013-9401-8","volume":"25","author":"FS Tristao","year":"2014","unstructured":"Tristao FS, Amar M, Latrous I, Del-Bel EA, Prediger RD, Raisman-Vozari R. Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson\u2019s disease. Neurotox Res. 2014;25:24\u201332.","journal-title":"Neurotox Res"},{"key":"280_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/nan.12493","volume":"45","author":"KC Wu","year":"2019","unstructured":"Wu KC, Liou HH, Lee CY, Lin CJ. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)\/1-methyl-4-phenylpyridinium (MPP(\u2009+\u2009))-induced alpha-synuclein accumulation and neurotoxicity. Neuropathol Appl Neurobiol. 2019;45:157\u201373.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"280_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc. 2007;2:141\u201351.","journal-title":"Nat Protoc"},{"key":"280_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0306-4522(01)00295-0","volume":"106","author":"E Petroske","year":"2001","unstructured":"Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP\/probenecid treatment. Neuroscience. 2001;106:589\u2013601.","journal-title":"Neuroscience"},{"key":"280_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1538\/expanim.14-0077","volume":"64","author":"S Olivan","year":"2015","unstructured":"Olivan S, Calvo AC, Rando A, Munoz MJ, Zaragoza P, Osta R. Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Exp Anim. 2015;64:147\u201353.","journal-title":"Exp Anim"},{"key":"280_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00401-012-0964-x","volume":"124","author":"GG Kovacs","year":"2012","unstructured":"Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012;124:37\u201350.","journal-title":"Acta Neuropathol"},{"key":"280_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5414\/NP300796","volume":"33","author":"U Unterberger","year":"2014","unstructured":"Unterberger U, Lachmann I, Voigtlander T, Pirker W, Berghoff AS, Flach K, et al. Detection of disease-associated alpha-synuclein in the cerebrospinal fluid: a feasibility study. Clin Neuropathol. 2014;33:329\u201334.","journal-title":"Clin Neuropathol"},{"key":"280_CR25","first-page":"893","volume":"128","author":"W Maetzler","year":"2014","unstructured":"Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, et al. In vivo markers of Parkinson\u2019s disease and dementia with Lewy bodies: current value of the 5G4 alpha-synuclein antibody. Acta Neuropathol. 2014;128:893\u20135.","journal-title":"Acta Neuropathol"},{"key":"280_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783\u2013801.","journal-title":"Cell"},{"key":"280_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/08923970802278557","volume":"30","author":"MA Panaro","year":"2008","unstructured":"Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, Mitolo V, et al. Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson\u2019s-like disease. Immunopharmacol Immunotoxicol. 2008;30:729\u201340.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"280_CR28","doi-asserted-by":"publisher","first-page":"8514","DOI":"10.1073\/pnas.1432609100","volume":"100","author":"S Lehnardt","year":"2003","unstructured":"Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A. 2003;100:8514\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"280_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.neuropharm.2018.04.008","volume":"144","author":"QH Shao","year":"2019","unstructured":"Shao QH, Yan WF, Zhang Z, Ma KL, Peng SY, Cao YL, et al. Nurr1: A vital participant in the TLR4-NF-kappaB signal pathway stimulated by alpha-synuclein in BV-2 cells. Neuropharmacology. 2019;144:388\u201399.","journal-title":"Neuropharmacology"},{"key":"280_CR30","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10571-017-0570-5","volume":"38","author":"H Jiang","year":"2018","unstructured":"Jiang H, Wang Y, Liang X, Xing X, Xu X, Zhou C. Toll-like receptor 4 knockdown attenuates brain damage and neuroinflammation after traumatic brain injury via inhibiting neuronal autophagy and astrocyte activation. Cell Mol Neurobiol. 2018;38:1009\u201319.","journal-title":"Cell Mol Neurobiol"},{"key":"280_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.bbrc.2016.09.109","volume":"479","author":"A Hoffmann","year":"2016","unstructured":"Hoffmann A, Ettle B, Bruno A, Kulinich A, Hoffmann AC, von Wittgenstein J, et al. Alpha-synuclein activates BV2 microglia dependent on its aggregation state. Biochem Biophys Res Commun. 2016;479:881\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"280_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ane.12247","volume":"130","author":"N Malek","year":"2014","unstructured":"Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson\u2019s disease-a systematic review. Acta Neurol Scand. 2014;130:59\u201372.","journal-title":"Acta Neurol Scand"},{"key":"280_CR33","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108:4194\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"280_CR34","doi-asserted-by":"publisher","first-page":"27230","DOI":"10.1074\/jbc.M212436200","volume":"278","author":"EH Norris","year":"2003","unstructured":"Norris EH, Giasson BI, Ischiropoulos H, Lee VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem. 2003;278:27230\u201340.","journal-title":"J Biol Chem"},{"key":"280_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.13234","volume":"135","author":"Y Xu","year":"2015","unstructured":"Xu Y, Deng Y, Qing H. The phosphorylation of alpha-synuclein: development and implication for the mechanism and therapy of the Parkinson\u2019s disease. J Neurochem. 2015;135:4\u201318.","journal-title":"J Neurochem"},{"key":"280_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2014.10.028","volume":"302","author":"N Dzamko","year":"2015","unstructured":"Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson\u2019s disease. Neuroscience. 2015;302:89\u2013102.","journal-title":"Neuroscience"},{"key":"280_CR37","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1177\/1535370215576313","volume":"240","author":"I Stojkovska","year":"2015","unstructured":"Stojkovska I, Wagner BM, Morrison BE. Parkinson\u2019s disease and enhanced inflammatory response. Exp Biol Med (Maywood). 2015;240:1387\u201395.","journal-title":"Exp Biol Med (Maywood)"},{"key":"280_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2015.04.014","volume":"283","author":"E Dursun","year":"2015","unstructured":"Dursun E, Gezen-Ak D, Hanagasi H, Bilgic B, Lohmann E, Ertan S, et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer\u2019s disease, mild cognitive impairment or Parkinson\u2019s disease. J Neuroimmunol. 2015;283:50\u20137.","journal-title":"J Neuroimmunol"},{"key":"280_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1236-z","volume":"15","author":"C Qiao","year":"2018","unstructured":"Qiao C, Zhang Q, Jiang Q, Zhang T, Chen M, Fan Y, et al. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP\/p mouse model of Parkinson\u2019s disease. J Neuroinflamm. 2018;15:193.","journal-title":"J Neuroinflamm"},{"key":"280_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0997-0","volume":"14","author":"J Qu","year":"2017","unstructured":"Qu J, Tao XY, Teng P, Zhang Y, Guo CL, Hu L, et al. Blocking ATP-sensitive potassium channel alleviates morphine tolerance by inhibiting HSP70-TLR4-NLRP3-mediated neuroinflammation. J Neuroinflamm. 2017;14:228.","journal-title":"J Neuroinflamm"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0280-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:13Z","timestamp":1684616533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-019-0280-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1038\/s41401-019-0280-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"25 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}